Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: GSK3536820A; MCV4 vaccine - Novartis; MenACWY-CRM; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline; Novartis; Tianjin CanSino Biotechnology
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 14 Feb 2018 GlaxoSmithKline plans a phase II trial in Meningococcal infections (Prevention, In adults, In children) in August 2018 (NCT03433482) (EudraCT2017-003456-23)
  • 12 Sep 2017 The Therapeutics Goods Administration approves Meningococcal vaccine groups A C Y W- 135 conjugate for treatment of Meningococcal infections (In Infants aged less than 12-months, Prevention) in Australia
  • 17 Jul 2017 GlaxoSmithKline completes a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA and Puerto Rico (IM) (NCT02986854)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top